Tokyo, Japan, June 21^th, 2023  - Taisho Pharmaceutical Co., Ltd., [Head Office: Toshima-ku, Tokyo; President: Shigeru Uehara] (hereinafter referred to as "Taisho") has entered into an exclusive licensing agreement with Biolinq Incorporated [Head Office: San Diego, CA, USA; CEO: Rich Yang] (hereinafter referred to as " Biolinq ") for the development and sales of its intradermal glucose sensor platform in Japan.

Under this agreement, Taisho and Biolinq will collaborate to obtain approval for Biolinq’s intradermal glucose sensor in Japan.  An upfront payment will be made as a consideration for this agreement and Taisho will have exclusive sales rights in the country.  Taisho has been a strategic investor since 2021.

Established in 2012, Biolinq is a private medtech company dedicated to the design and manufacturing of biowearable technologies.  Its core technology leverages innovation from the semiconductor industry to miniaturize electrochemical sensors for consumer health applications, starting with metabolic health.  Biolinq’s ultra-small array of biosensors are designed to measure glucose levels just beneath the surface of the skin and a user interface is built directly into the wearable device to uniquely inspire and inform healthy lifestyle choices with real-time feedback. 

Taisho has been involved in the research, development, and sales of a wide range of fields in consumer health and wellness, including prescription pharmaceuticals, OTC drugs, cosmetics, and functional foods with health claims.  With this newly executed agreement, Taisho intends to expand its business into the medical device field with long term commitments and contributions towards better consumer health.

For more information about Biolinq, please visit their website at www.biolinq.com.

(The Biolinq Sensor is an investigational device that is not yet cleared or approved by the FDA or any other regulatory authority.)